Clinical Trial Update: Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT [Phase 2]

View source ↗

Summary

Phase 2 pilot study assessing perampanel (E2007) effects on synaptic dopamine in mild-to-moderate Parkinson's disease using [123I]-IBZM SPECT; study terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Perampanel (perampanel)

Snippet

Sponsor: Eisai Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: TERMINATED | Results posted: 2012-12-24